Lewes, DE -- (SBWIRE) -- 07/23/2013 -- LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. Out Today’s Focus is on: Alliqua Inc (OTCMKTS:ALQA), Eastman Kodak Company (OTCMKTS:EKDKQ), FUSE SCIENCE, INC (OTCMKTS:DROP), MYOS Corp (OTCMKTS:MYOS)
Alliqua Inc (OTCMKTS:ALQA) opened the session at $0.08, remained amid the day range of $0.07 - $0.08, and recently traded at $0.0750. The stock showed a negative performance of -6.25% in the recent trading session. The stock gained a volume of 543,592 shares and the average volume of the stock remained 240,901 shares. Alliqua, Inc., a biopharmaceutical company, focuses on the development, manufacture, and distribution of proprietary transdermal wound care and drug delivery technologies. The company offers water content, electron beam cross-linked, and aqueous polymer hydrogels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics.
Has ALQA Found The Bottom and Ready To Move Up? Find Out Here
Eastman Kodak Company (OTCMKTS:EKDKQ) traded with volume of 339,580 shares in the recent trading session and the average volume of the stock remained 4.08 million shares. The 52 week range of the stock remained $0.08- $0.61. The stock was recently trading at $0.126. The market capitalization of the stock remained 34.29 million. Eastman Kodak Company engages in commercial imaging business. It operates through three segments: the Graphics, Entertainment and Commercial Films (GECF); the Digital Printing and Enterprise (DP&E); and the Personalized and Document Imaging (P&DI).
Can Investors Bet on EKDKQ after this News update? Find out in this Research Report
FUSE SCIENCE, INC (OTCMKTS:DROP) exchanged 499,795 shares and the average volume remained 1.44million shares. The stock escalated 2.74% and was moving at $0.0899. The beta of the stock remained -0.31 and the EPS of the stock remained -0.08. Fuse Science, Inc., a consumer products company, develops alternative delivery systems with applications in the sports nutrition and medical fields. Its delivery systems include sublingual and transdermal delivery technologies that enable energy, medicines, vitamins, and minerals to bypass the gastrointestinal tract and enter the blood stream directly.
What was the Moving Force behind DROP On Bullish Run? Read This Research Report
MYOS Corp (OTCMKTS:MYOS) gained volume of 175,500 shares, while the average volume remained 254,180 shares. The stock advanced 1.29% and remained at $0.142. The EPS of the stock remained -0.05. The one month trend of the stock was -28.74% and the three month trend remained negative -5.47%. MYOS Corporation, a development stage company, focuses on the discovery, development, and commercialization of nutritional supplements, functional foods, therapeutic products, and other technologies for maintaining or improving the health and performance of muscle tissue. It develops MYO-T12, a natural-myostatin inhibitor that is used to optimize biological activity.
For How Long MYOS will fight for Profitability? Read This Trend Analysis report
About LeadingStockAlerts:
LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community.
Our site has been the clear choice for today’s investors and day-traders. As one of the internet’s premiere financial destinations, we offer the investment community some of the market’s leading emerging opportunities. Using a balanced combination of industry experience and high-tech offerings, this site keeps you ahead of the curve and ahead of the bell.
Disclaimer:
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Read Full Disclaimer at: http://leadingstockalerts.com/disclaimer/